Ibrutinib, a small molecule inhibitor of Bruton’s tyrosine kinase (BTK), has been successfully used in the treatment of refractory AIHA among chronic lymphocytic leukaemia patients (49, 50) and could be an option to consider in PID. The gene discussed is BTK; the disease is B-cell chronic lymphocytic leukemia.